1[1]Wu HH,Wilcox GL,Mcloon SC.Implantation of AtT-20 or genetically modified AtT-20/hENK cells in mouse spinal cord induced antinociception and opioid tolerance.J Neurosci,1994,14:4806～4814.
2[2]Sagen J. Cellular transplantation for intractable pain. Adv Pharmacol, 1998, 42:579～582.
3[3]Iadarola MJ, Lee S, Mannes AJ. Gene transfer approaches to pain control. Molecular Neurobiology of Pain ,1997; (IASP Press, Seattle W.A.).
4[4]Anderson WF. Human gene therapy. Nature (London), 1998, 392: 25～30.
5[5]Dai Y, Roman M, Naviaux RK, et al. Gene therapy via primary myoblasts: long term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci USA, 1992, 89:10892～10895.
6[6]Yu XM, Salter MW. Src, a molecular switch governing gain control of synaptic transmission mediated by N-methyl-D-aspartate receptors. Proc Natl Acad Sci USA, 1999, 96:7697～704.
7[7]Garry MG, Malik S, Yu J, et al. Knock down of spinal NMDA receptors reduces NMDA and formalin evoked behaviors in rat. Neuroreport, 2000, 11:49～55.
8[8]Finegold AA, Perez FM, Ladarola MJ. In vivo control of NMDA receptor transcript in motoneurons by viral transduction of a short antisense gene. Brain Res Mol Brain Res, 2001, 90:17～25.
9[9]Delander GE,Schott E,Brodin E,et al. Spinal expression of mRNA for immediate early genes in a model of chronic pain. Acta Physiol Scand, 1997, 161:517～25.
10[10]Zimmermann M, Herdegen T. Plasticy of the nervous system at the systematic, cellular and molecular levels: a mechanism of chronic pain and hyperalgesia. Prog Brain Res, 1996, 110:233～59.
